Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374499 · ClinicalTrials.gov registry record · Phase 4
Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions
A Phase 4 study of Post Operative Pain, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT05374499 is a Phase 4 study of Post Operative Pain that has completed, run by University of Southern California. The registered enrollment target is 73 participants, below the 235-participant average among 56 other Post Operative Pain trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05374499, a Phase 4 study of Post Operative Pain, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The most prevalent complaint after third molar extractions is pain. There have been many modalities and regimens developed to manage post-operative pain, such as modifications in surgical techniques, locally-applied medicaments, and oral analgesics. Recently, liposomal bupivacaine (Exparel) has been FDA approved for single-dose infiltration in the oral cavity in adults and children (6 years or older) to produce extended postsurgical local anesthesia. We hypothesize that the administration of liposomal bupivacaine (Exparel) at the end of third molar extractions will decrease postoperative pain and decrease narcotic use for pain management.
Conditions Studied
Interventions
- DRUG Liposomal bupivacaine
- DRUG 0.5% bupivacaine with 1:100,000 epinephrine
Study Locations (1)
California
- Herman Ostrow School of Dentistry of USC - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05374499
The ClinicalTrials.gov registry entry for NCT05374499 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 56 other Post Operative Pain trials with a reported enrollment target (69% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Operative Pain appearing as the primary indexed condition, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT05374499 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05374499 about?
NCT05374499 is a clinical study titled "Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions". The most prevalent complaint after third molar extractions is pain. There have been many modalities and regimens developed to manage post-operative pain, such as modifications in surgical techniques, locally-applied medicaments, and oral analgesics. Recently, liposomal bupivacaine (Exparel) has been...
What is the current status of trial NCT05374499?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2022-09-01. Estimated completion is 2024-05-01.
What conditions does trial NCT05374499 study?
This clinical trial studies the following conditions: Post Operative Pain.
What interventions are being tested in trial NCT05374499?
The interventions under investigation include: Liposomal bupivacaine (DRUG), 0.5% bupivacaine with 1:100,000 epinephrine (DRUG).
Who is sponsoring clinical trial NCT05374499?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05374499 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Operative Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi
RECRUITING · Phase 4
-
Preoperative Acetazolamide
RECRUITING · Phase 4
-
Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study
RECRUITING · Phase 4
-
Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
RECRUITING · Phase 4
-
Post Operative Infusion Pump Pain Study
RECRUITING · Phase 4
-
ZYNRELEF for Pain Management in Total Knee Arthroplasty
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.